QCG
SNDX icon

Quadrant Capital Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Quadrant Capital Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71 Hold
3
– – ﹤0.01% 2698
2025
Q4 		$64 Hold
3
– – ﹤0.01% 2698
2025
Q3 		$47 Buy
+3
New +$39 ﹤0.01% 2667
2025
Q2 		– Sell
-194
Closed -$2.38K – 2434
2025
Q1 		$2.38K Sell
194
-824
-81% -$11.6K ﹤0.01% 2487
2024
Q4 		$13.5K Sell
1,018
-1,661
-62% -$28.4K ﹤0.01% 2034
2024
Q3 		$51.6K Buy
2,679
+187
+8% +$3.86K ﹤0.01% 1435
2024
Q2 		$51.2K Sell
2,492
-75
-3% -$1.57K ﹤0.01% 1394
2024
Q1 		$61.1K Buy
2,567
+126
+5% +$2.81K ﹤0.01% 1277
2023
Q4 		$52.8K Buy
2,441
+1,496
+158% +$23K ﹤0.01% 1359
2023
Q3 		$13.7K Buy
945
+933
+7,775% +$17.6K ﹤0.01% 1867
2023
Q2 		$252 Sell
12
-116
-91% -$2.42K ﹤0.01% 2641
2023
Q1 		$2.7K Hold
128
– – ﹤0.01% 2371
2022
Q4 		$3.26K Hold
128
– – ﹤0.01% 2306
2022
Q3 		$3K Hold
128
– – ﹤0.01% 2298
2022
Q2 		$2K Buy
+128
New +$2.13K ﹤0.01% 2280

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Quadrant Capital Group's SNDX Position: Q1 2026 in Review

Quadrant Capital Group held its Syndax Pharmaceuticals (SNDX) position steady in Q1 2026 at 3 shares worth $71. The position accounts for ﹤0.01% of the portfolio, ranked #2698.

Quadrant Capital Group first reported a position in SNDX in Q2 2022 and has held it in 15 quarters since. The position peaked at $61.1K in Q1 2024. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Quadrant Capital Group held 3 shares of Syndax Pharmaceuticals worth $71 as of Q1 2026.
  • Quadrant Capital Group left its Syndax Pharmaceuticals share count unchanged in Q1 2026.
  • Syndax Pharmaceuticals made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2698 holding.
  • Quadrant Capital Group first reported a position in Syndax Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • Quadrant Capital Group's Syndax Pharmaceuticals position peaked at $61.1K in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.